^
Association details:
| Biomarker: | HAVCR2 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Jemperli (dostarlimab-gxly) (PD1 inhibitor) + cobolimab (TSR-022) (TIM-3 antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy
Published date:
11/04/2023
Excerpt:
Patients with irRECIST defined partial response or stable disease (n=12) had higher baseline TIM-3 immunohistochemistry (research use only assay) levels versus patients with progressive disease (n=22; p=0.013); a similar trend was observed for ORR….Cobolimab plus dostarlimab showed early evidence of efficacy and acceptable safety in patients with advanced/metastatic NSCLC.
DOI:
http://dx.doi.org/10.1136/jitc-2023-SITC2023.0596
Trial ID:
